Nilambra Dogra et al., 2012-08-31: Dogra and Mukhopadhyay report that fenbendazole inhibits proteasome activity in cancer cells, causing accumulation of cyclins, p53 and IkappaB-alpha and endoplasmic-reticulum stress.
We show here, using fluorogenic substrates, that FZ treatment leads to the inhibition of proteasomal activity in the cells.
Nilambra Dogra et al., 2012-08-31: Dogra and Mukhopadhyay report that fenbendazole inhibits proteasome activity in cancer cells, causing accumulation of cyclins, p53 and IkappaB-alpha and endoplasmic-reticulum stress. Study type: human NSCLC cell lines in vitro. N: not applicable. Country: India (Panjab University, Chandigarh). Dose: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: no COI statement in the record. Comparator: normal cells, which the authors report are not growth-inhibited. This is the earlier mechanism paper behind the 2018 Dogra study. Study type: lab.
